Literature DB >> 6093075

Ceruletide, ceruletide analogues and cholecystokinin octapeptide (CCK-8): effects on isolated intestinal preparations and gallbladders of guinea pigs and mice.

G Zetler.   

Abstract

The smooth muscle stimulatory effects of cholecystokinin octapeptide (CCK-8), ceruletide (CER), ten analogues of CER, and carbachol were studied in isolated organs of the guinea pig and the mouse (stomach, ileum, duodenum, colon and gallbladder). On a molar basis, CCK-8 and CER had in all organs except stomach greater potency (lower EC50) than carbachol. The effectiveness (Emax) of CCK-8 and CER was in the gut less than that of carbachol, in the guinea pig gallbladder equal with and in the mouse gallbladder superior to that of carbachol. The alteration of peptide structure was virtually without influence on effectiveness; however, it greatly modified the potency and the organ selectivity of the effect. There was no clear-cut correlation between the potency to stimulate smooth muscle and to alter the behavior of the mouse.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6093075     DOI: 10.1016/0196-9781(84)90014-7

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  3 in total

1.  Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist.

Authors:  R S Chang; V J Lotti
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

2.  Effect of CCK receptor antagonists on the antinociceptive, reinforcing and gut motility properties of morphine.

Authors:  L Singh; R J Oles; M J Field; P Atwal; G N Woodruff; J C Hunter
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

3.  Characterization of CCK receptors in a novel smooth muscle preparation from the guinea-pig stomach by use of the selective antagonists CI-988, L-365,260 and devazepide.

Authors:  S J Boyle; K W Tang; G N Woodruff; A T McKnight
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.